Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PLK1 | P53350 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764373 | 0.96 | TSHR (0.62) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL13618628 | 0.89 | TSHR (0.64) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL10181988 | 0.88 | TSHR (0.62) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL4102493 | 0.88 | TSHR (0.62) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL12052569 | 0.88 | TSHR (0.66) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL13618149 | 0.88 | TSHR (0.62) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL10181902 | 0.86 | TSHR (0.64) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL1764374 | 0.86 | TSHR (0.61) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL13091199 | 0.86 | TSHR (0.67) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL89401 | 0.85 | TSHR (0.71) | TSHRHTTPOLBTP53PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-10087151-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3091984-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | TSHR 2505/4885HTT 1858/4885POLB 609/4885 |
| US-10611741-B2 | Substituted benzoxazine and related compounds | ABCG2, XDH, CYP3A5 | TSHR 3319/4885HTT 1626/4885POLB 3506/4885 |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | TSHR 2505/4885HTT 1858/4885POLB 609/4885 |
| US-10087151-B2 | Substituted benzoxazine and related compounds | CYP4B1, XDH, UGT2B7 | TSHR 2505/4885HTT 1858/4885POLB 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.